International Superstar and Business Mogul Flo Rida's JettSet1 Enterprises and Biom Therapeutics Partner To Bring the First and Only Cannabinoid-Derived, FDA Approved Orphan Status Therapeutic Agent To Treat 'Angelman Syndrome'
).Biom Therapeutics is a preclinical-stage company which has an initial focus on rare childhood diseases.
- ).Biom Therapeutics is a preclinical-stage company which has an initial focus on rare childhood diseases.
- Biom Therapeutics has extensively researched Cannabidiol (CBD)-based drugs and their efficacy in specifically treating neurodevelopmental conditions.
- Biom Therapeutics' patent-pending water-soluble CBD, nano-dispersion, sugar-free, child-friendly formulations improve effectiveness and treatment compliance.
- The FDA designated the lead drug candidate, BIO017, the first and only therapeutic agent with orphan drug approval status in March 2021 for the treatment of Angelman Syndrome.